{"name":"Sumitomo Pharma Switzerland GmbH","slug":"sumitomo-pharma-switzerland-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Relugolix Combination Therapy","genericName":"Relugolix Combination Therapy","slug":"relugolix-combination-therapy","indication":"Advanced prostate cancer requiring androgen deprivation therapy","status":"phase_3"},{"name":"Relugolix Combination Tablet","genericName":"Relugolix Combination Tablet","slug":"relugolix-combination-tablet","indication":"Prostate cancer","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Cultured Thymus Tissue","genericName":"Cultured Thymus Tissue","slug":"cultured-thymus-tissue","indication":"Immunodeficiency disorders","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Relugolix + Estradiol + Norethindrone Acetate","genericName":"Relugolix + Estradiol + Norethindrone Acetate","slug":"relugolix-estradiol-norethindrone-acetate","indication":"Moderate to severe pain associated with endometriosis in women of reproductive potential","status":"marketed"}]}],"pipeline":[{"name":"Relugolix Combination Therapy","genericName":"Relugolix Combination Therapy","slug":"relugolix-combination-therapy","phase":"phase_3","mechanism":"Relugolix is a gonadotropin-releasing hormone (GnRH) antagonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to rapid reduction of testosterone and estrogen levels.","indications":["Advanced prostate cancer requiring androgen deprivation therapy","Hormone receptor-positive breast cancer (in combination with other therapies)"],"catalyst":""},{"name":"Cultured Thymus Tissue","genericName":"Cultured Thymus Tissue","slug":"cultured-thymus-tissue","phase":"marketed","mechanism":"Cultured thymus tissue provides thymic factors and hormones that support immune system development and T-cell maturation.","indications":["Immunodeficiency disorders","Thymic insufficiency"],"catalyst":""},{"name":"Relugolix + Estradiol + Norethindrone Acetate","genericName":"Relugolix + Estradiol + Norethindrone Acetate","slug":"relugolix-estradiol-norethindrone-acetate","phase":"marketed","mechanism":"Relugolix suppresses luteinizing hormone and follicle-stimulating hormone by antagonizing GnRH receptors, while estradiol and norethindrone acetate provide hormone replacement to manage menopausal symptoms in women with endometriosis.","indications":["Moderate to severe pain associated with endometriosis in women of reproductive potential"],"catalyst":""},{"name":"Relugolix Combination Tablet","genericName":"Relugolix Combination Tablet","slug":"relugolix-combination-tablet","phase":"phase_3","mechanism":"Relugolix combination tablet works by inhibiting gonadotropin-releasing hormone (GnRH) receptors, leading to a decrease in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) production, which in turn reduces testosterone levels.","indications":["Prostate cancer","Endometriosis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTFB1N2d4NnYwN0JiU181Tm9vV0dUM1c1NWVMUHNCdlZFVmRSZXpmRFp3TnBQUVJXYnFYV1VlNVBIZXU0TzY4bE5BNTd4NGpIT21aYlZHMy1qSW1HWDFH?oc=5","date":"2026-04-06","type":"pipeline","source":"BioSpace","summary":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees - BioSpace","headline":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQRkp1ZXljVUJGaHVwSGdmeksyMnRwZE9BUXZFYWxUbVhJbEFnZzlXTHk1cWxDVlhpZnhvUERqWGJFV0lRUEFBZWxUeGxEcUhBdEdldk9JTnFEb252dU1jdDQ5MWNxZVlUWjZVTGZvS2FPeGVIR0xHNkRHSUVab0FwelVjMUg4aTREczJRb08wOGFNUTVNSkpJ?oc=5","date":"2026-02-23","type":"pipeline","source":"Medscape","summary":"Which Type of Prostate Cancer ADT Is Safer for the Heart? - Medscape","headline":"Which Type of Prostate Cancer ADT Is Safer for the Heart?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxPQjVBeGZOQ2pTalZiY2tITDVlUWtVTC1YcnAzZ05Sd2Npclc3SUR1MGJMa2QtRFNKZFNVTlZzRzVQZXYzTTBHWTJKaHNRZTNNV01LcjAtTXNDWGxkUV9mQjA4NTBsOFZmR1NMRjNjMnVZeUR2aWRIbnI3bllpaGxWMDdkTFlOSWdMLWt2QlYyak1HUkUycHZaZEZJQXlSa1NDZXVERklzLVNxdHhBZVhXQk93VTBleGpXVmkxenRaNlppTzd6TXZLaDdNTThxcURPNG1kbTVlbDFUREs1UnpScmZfWHJGbFJvSWpkaWhrT2QtQlFuR3BvX1RGbmM5VnZNN3dr?oc=5","date":"2025-11-03","type":"regulatory","source":"PR Newswire","summary":"Sumitomo Pharma America to Present New Investigational Data at the 2025 American Society of Hematology Annual Meeting - PR Newswire","headline":"Sumitomo Pharma America to Present New Investigational Data at the 2025 American Society of Hematology Annual Meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxQM1FqeGtxTzV1NVJWaXlNWEtwYmRJcF9zVm5vd3RzQ1llRUhCaU5sRV9TVFlsOFpFczdZRWx3NFpqUlJ5cEF1bFpZRnM0UXFOSVlVVzZwUTRuNWYtZ21RM2tFYWR5STFEWW5qRUxiY0FjMGpZcHcteUlXVGtpZWlZTlcyYXNCOE1LS2ZYcjVlVlhwaVlualMta3pkck1VTDY4YnE1RTdkMDFLRjExamJYSlZXMDQ4VzR3ZnYxbDZnQlFHUW1BRGlyT21LSjh0Q25ycjZYREZUWGg3OENZejYwdQ?oc=5","date":"2025-10-14","type":"earnings","source":"Investing.com","summary":"Earnings call transcript: Sumitomo Dainippon Pharma Q1 2025 sees strong North American sales - Investing.com","headline":"Earnings call transcript: Sumitomo Dainippon Pharma Q1 2025 sees strong North American sales","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxOYlJ6NFB3RHF3bEZjSlNqZ3pXalZsdjlkRXdvU2xDX0dsOXdhc29SaXVJWXpvUS11RmpoNTMtZmtrX3lNdnBWeHZ2QzBFT3F2UWdUUU5pN0Y5MGZJeGg3bklraGQ3Y2RuLUtRVFZqT0lsQ21uZWVyNkRteHQ2LVFjeFNLcEFxaVVfQWh0WDh0bGlZdm44eGlCLXpMYXVrQWhxcEc4cTZVZGU0bDVOX0lEVkdYQ0NQaFotYWNVYnFCVnNLREVlMU9Ud1Q4Q0FyZjNWeHoxRmZyWnBaZGpyN0NXcThYNHoyVFVsY3pGcTRxQmZjLUs0eTFxZTRaS09UZi14d3V1YlI0WExPWEU4bW1rdlVqUmN3RTFjME5EUDJfVjNRaUtxVWZVZlhsY25yZGhvTzNJeHhXWTlLUmtaSFE?oc=5","date":"2025-07-30","type":"pipeline","source":"PR Newswire","summary":"Sumitomo Pharma America Announces that the European Medicines Agency Has Granted Orphan Drug Designation to Nuvisertib (TP-3654) for the Treatment of Myelofibrosis - PR Newswire","headline":"Sumitomo Pharma America Announces that the European Medicines Agency Has Granted Orphan Drug Designation to Nuvisertib (","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAJBVV95cUxQYm9sR0FJN2xmckEwWmxfcXRXMDV5OXE2bXpVT2JoeG5NSmZBTmlHMGNQblYwUGNOcXlwaVk2aF9xYmstSUJ3bDExdHBCakx0Wk1jQUJhbDB6OVctZG9CS2s1aG1SSnAteC03Q0hacFRCcC1GY1E5SnF5VU83MEdzTVBHRXRCaDM3SUtzZW02OW9vYkNqc3AyYl9HYWlmNmhhTUdWQ2U3QTA1RXBHdnJ0ZzJuT0NJUXo1d1YzS2NCcVBNX0RyU0l0cTBremw3dkwxVnh3LW5UWmxiWlZmWFpuQXRla0pDVWoyX2daTHc4andQaUlVd3hxck1IR29rRWtLTGZsQnJ3bDRjel9kZVhRRF81b1o2ckJ3Q1k3dzJ6NTFGUFAzZnltR3N6aV9pTFoxc2dGUDJKdWtsXzZjYUZqZA?oc=5","date":"2025-06-30","type":"earnings","source":"PR Newswire","summary":"Sumitomo Pharma America and Former Professional Quarterback Rodney Peete Say it's Time to Go™ and Put Yourself First with Overactive Bladder Treatment Option GEMTESA® - PR Newswire","headline":"Sumitomo Pharma America and Former Professional Quarterback Rodney Peete Say it's Time to Go™ and Put Yourself First wit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwJBVV95cUxQeXVOdHVmU1U2cFRGZ0xWM3hVQ2hERkItUDR1TVJHOC02Wkh2T3NkWXZhRk1UZ2lxN05Wc0R6NnlyM2d6OVdhZC1rcVYxV0hZcldWeEtON1l0T2VFc2xDZngwUTl4X0RNUS1UbnNFTExYdzlGQ3E3QnZKUjlBcVNXUjc3M0g4NjRHaVAyWkxIbHBBOGVILU9RaThINUFvOERieXpUTFZ0ek9SQVk4RkExUXN3ZmtPSVFnUTAyNVEweGxRcVBoNHh4QnYyZTJvaGZBUUQ0R1dTSnlTWm5HRFI5MmRYamd2NzQwRnNlQVN0SDJEQzRDVDNCbFhDZi1RQzVOTnNvY29PQ3hZcDFfZUhVMnVZSm0tOG5wcldXQzVOLV9sMmFqdC0w?oc=5","date":"2025-06-05","type":"pipeline","source":"GlobeNewswire","summary":"Knight Therapeutics and Sumitomo Pharma enter into - GlobeNewswire","headline":"Knight Therapeutics and Sumitomo Pharma enter into","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOY3NfX1kwS0gwUHhPNEY2cnhINUxhZXQ4eE5SaTNYSWs1N1dpajdCU3ZVVm9FSEFZckF2YlZmREhjWHZoVXVEMHhvNWhOSnBjTmpMS00xVm9YXzdOR3BLTkdadVhBemREMW9YUGg1ZUxVRWMyeUdkRE1FYVY0RkJ4ZVByWlVXQXdQVUk5Y1RFUmtLR1BUam1qbXhwZ0NRaWVDWVNIeThhSmphU2gtWVhTWnBCSEw?oc=5","date":"2025-05-21","type":"pipeline","source":"Fortune Business Insights","summary":"METASTATIC CASTRATION-RESISTANT PROSTATE CANCER THERAPEUTICS MARKET TRENDS - Fortune Business Insights","headline":"METASTATIC CASTRATION-RESISTANT PROSTATE CANCER THERAPEUTICS MARKET TRENDS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQdUNlMUNGVTM2bnBSSHhMQ3gza29wbll4OFV6U1k1Z1A3UDd2YmxENmZKeFJVc2o2cGhHa3d0aXhGa0tnTUJyOTFvT1E1Qzc5aTNYdXFtR2dLTS04MXpWNnoyeTBfa3Z0UDFEVkdta2JlUm13NGVqd3dsRGpLWjNTN3VDQ0FGSnM3N0RZR3UtdF9fWW9yZVhZaldvSzgwV2FqNndkbVZWZmlXdHRlaTFVYXBPTjhuMWkzYmNiWjRJOVBfVVV0U01EVVF6Zw?oc=5","date":"2025-05-09","type":"pipeline","source":"dovepress.com","summary":"PPA - dovepress.com","headline":"PPA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNeExOQy1pZTNUZ3N6WFlremQtWDI3RWdHTVBNNDIwc29BSGRMT2lJdFlCekRGdHAyTE9PemRjYV9nQnd5VWpKZTA3SnNhX0w0UTBvZEhxUmNhajRQS1JiZDFpZzM0MzdfVmFLWEpra05qcU54bWRHY0hVdUhEYzZqNVRCQUVDSnRCbUtwaV9NVzI1OEpTYW9fLXQ0VVBvRFZYNjJpZm0tSGEtMk1RZkxwWWp3Rko?oc=5","date":"2025-03-20","type":"earnings","source":"Life Sciences Intellectual Property Review","summary":"Takeda, Pfizer, and Sumitomo sue to protect $379m Orgovyx revenue - Life Sciences Intellectual Property Review","headline":"Takeda, Pfizer, and Sumitomo sue to protect $379m Orgovyx revenue","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE9zSWc4QWY3UW53Q1BYNTB3bXVISHdLZVVPcGIyb2RWY0hmM2s3OEtJeHdDcTB2ajVsYWZXRnRUOGdaMGU1UmhlelVZVnpxUmJIN2JaelFUTjJ1aVp1b3puSE9zeE4yTWNqNzFKc0lRS05XUFhD?oc=5","date":"2024-11-18","type":"pipeline","source":"Taylor & Francis Online","summary":"Testosterone recovery post discontinuation of androgen deprivation for the treatment of advanced prostate cancer - Taylor & Francis Online","headline":"Testosterone recovery post discontinuation of androgen deprivation for the treatment of advanced prostate cancer - Taylo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNcDB4ZFl0OElQSjNHd0x4NTRqSXdVMlZfVkxLRlZnYk4wZzZnSl81YVlaWDEySXh6OGxIdzRrNUNXVDhXM2lFdnlRdlRkQTdGTFVvcmlXNDQ1dllZSGt0N21HUWdfZDdCSnRfMUI0Z1ZkdWVocWlLZGdteGo0bTFaV001TGdVbDNsVGpERHZDc2Z0OHc1UzlYam9TOXJIV29TWWc5UjRWUXQ?oc=5","date":"2024-11-04","type":"pipeline","source":"drugdiscoverytrends.com","summary":"Roche, Novartis lead 2024’s top 50 pharma in oncology (YTD) - drugdiscoverytrends.com","headline":"Roche, Novartis lead 2024’s top 50 pharma in oncology (YTD)","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":2,"marketed":2},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}